Solventum

SOLV

Market cap $14.8B

ST. PAUL, Minn. , Nov. 25, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Piper Sandler Healthcare Conference on Tuesday, Dec. 2, 2025, beginning at approximately 10:00 a.m.

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings, a $900 million market segment in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn.

ST. PAUL, Minn. , Nov. 20, 2025 /PRNewswire/ -- Solventum  (NYSE: SOLV) announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $1 billion of the Company's outstanding common stock.

Solventum Corporation ( SOLV ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Wayde McMillan - Chief Financial Officer Doug Bartlett Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Frederick Wise Stifel, Nicolaus & Company, Incorporated, Research Division Luckily, Wayde is not the Chief Executive Officer. He tells me, I'm not sure.

Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?

Solventum (SOLV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Solventum which has barely moved since our coverage 14 months back, delivered mixed Q3 results last week. SOLV managed to beat both topline and bottomline estimates (although the degree of beat on the latter wasn't as strong as previous quarters), but revenue trends continue to slow. Margin pressures persist due to tariffs (the impact of which will be worse next year), but SOLV's new multi-year restructuring program and its ongoing efforts on programmatic savings may provetobehandy.

Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.

Solventum Corporation ( SOLV ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - CEO & Director Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Travis Steed - BofA Securities, Research Division Lei Huang - Wells Fargo Securities, LLC, Research Division Presentation Operator Good afternoon. My name is Regina, and I will be your conference operator today.